IBD Management: Vedolizumab, Ustekinumab, and JAK Inhibitors in UC and Crohn Disease
Sam Anderson
Vedolizumab: Gut-Selective Integrin Blockade
The therapeutic landscape for ulcerative colitis and Crohn disease has expanded far beyond TNF inhibitors. For the gastroenterologist managing moderate-to-severe IBD, the treatment algorithm now includes four distinct mechanisms of action — anti-TNF agents, gut-selective integrin blockade (vedolizumab), IL-12/23 blockade (ustekinumab), and JAK inhibitors (tofacitinib, upadacitinib) — each with head-to-head data, disease-specific positioning, and distinct safety profiles. The clinical challenge is selecting the right agent for the right patient, sequencing therapies rationally after failure, and navigating the safety implications of each mechanism in the context of the individual patient's comorbidities and risk factors.
Vedolizumab, an anti-α4β7 integrin antibody, provides gut-selective immunosuppression without systemic immune compromise. In the GEMINI 1 trial (UC), vedolizumab achieved clinical remission in 42% versus 16% placebo at week 52[1]. In GEMINI 2 (Crohn disease), remission rates were more modest at 39% versus 22% for placebo[2]. The VARSITY trial directly compared vedolizumab to adalimumab in UC, demonstrating vedolizumab superiority for clinical remission at week 52 (31% vs 23%, p=0.006) and mucosal healing (40% vs 28%)[3].
Vedolizumab is generally positioned as first-line biologic in moderate-to-severe UC given the VARSITY data and its favorable safety profile. In Crohn disease, it is most effective in TNF-naive patients and may have slower onset than TNF inhibitors, making it less ideal for patients requiring rapid disease control.
Ustekinumab: IL-12/23 Blockade
Ustekinumab targets the p40 subunit shared by IL-12 and IL-23. The UNITI trials demonstrated clinical response in 56% of TNF-failure Crohn patients at week 6 with IV induction (6 mg/kg)[4]. Maintenance with 90 mg SC every 8 weeks achieved clinical remission in 54% at week 44[5]. In UC, the UNIFI trial showed 44% remission at week 44 with q8w dosing[6]. Ustekinumab offers particular utility in patients with concomitant psoriasis or psoriatic arthritis, and in TNF-experienced Crohn disease patients where it has demonstrated consistent efficacy.
JAK Inhibitors: Tofacitinib and Upadacitinib
Tofacitinib (10 mg BID induction, 5-10 mg BID maintenance) was the first oral small molecule approved for UC, achieving remission in 41% versus 11% placebo at week 52 in OCTAVE Sustain[7]. Upadacitinib, a more selective JAK1 inhibitor, demonstrated superior efficacy in the U-ACHIEVE and U-ACCOMPLISH trials (UC induction remission 26-34% vs 4-5% placebo at week 8)[8] and is also approved for Crohn disease based on the U-EXCEL and U-EXCEED trials (clinical remission 50-52% vs 29% placebo at week 52)[9].
JAK Inhibitor Safety: Navigating the ORAL Surveillance Signal
The ORAL Surveillance trial in rheumatoid arthritis showed increased rates of MACE and malignancy with tofacitinib versus TNF inhibitors in patients over 50 with cardiovascular risk factors. The FDA subsequently added boxed warnings to all JAK inhibitors. In IBD-specific data, the absolute cardiovascular and malignancy risk appears lower given the younger patient population, but current guidelines recommend JAK inhibitors after failure of at least one biologic in patients over 65 or those with cardiovascular risk factors. VTE risk is dose-dependent and requires clinical vigilance.
Treatment Sequencing: A Practical Approach
For moderate-to-severe UC in biologic-naive patients, vedolizumab or infliximab represent reasonable first-line options. In Crohn disease, anti-TNF agents (infliximab, adalimumab) or ustekinumab are preferred first-line depending on disease phenotype. Perianal Crohn disease favors infliximab based on ACCENT II data[10]. After first biologic failure, mechanism switching (rather than within-class cycling) is supported by higher response rates: TNF failure patients respond better to vedolizumab, ustekinumab, or JAK inhibitors than to a second TNF agent. Combination therapy with an immunomodulator (azathioprine or methotrexate) improves infliximab and adalimumab efficacy but is not established for vedolizumab, ustekinumab, or JAK inhibitors.
Monitoring and Treat-to-Target
Modern IBD management increasingly embraces a treat-to-target approach where the therapeutic goal extends beyond symptomatic improvement to objective mucosal healing confirmed by endoscopy or biomarkers. Fecal calprotectin is the most practical non-invasive marker for monitoring mucosal inflammation — levels consistently below 150-250 mcg/g correlate well with endoscopic remission and can be used to guide treatment decisions between endoscopies. The clinical principle is straightforward: a patient who feels well but has persistently elevated calprotectin is likely still inflamed and at risk for relapse or complications, while a patient with normalized biomarkers has a more favorable long-term trajectory. Therapeutic drug monitoring of anti-TNF agents and vedolizumab can guide dose optimization before concluding primary failure, as subtherapeutic drug levels due to immunogenicity or rapid clearance account for a significant proportion of apparent treatment failures.
Limitations and Evolving Questions
Despite the expansion of the IBD therapeutic armamentarium, head-to-head trials between advanced therapies remain scarce — VARSITY (vedolizumab versus adalimumab in UC) is the only large head-to-head biologic comparison published to date, and no equivalent trial exists for Crohn disease. The optimal positioning of JAK inhibitors in UC and Crohn disease relative to biologics is still being defined by emerging real-world evidence. Whether dual advanced therapy (combining two biologics or a biologic with a JAK inhibitor) is safe and effective in refractory IBD is an area of active investigation that lacks randomized trial support. And the long-term implications of earlier biologic initiation — starting advanced therapy before exhausting conventional immunomodulators — represent a philosophical shift in IBD management that is supported by logic but not yet by decades of outcomes data.
References
- Vedolizumab as induction and maintenance therapy for ulcerative colitis (GEMINI 1)
- Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (VARSITY)
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (UNITI)
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (UNITI)
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis (UNIFI)
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (OCTAVE)
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis (U-ACHIEVE and U-ACCOMPLISH)
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)
- Infliximab maintenance therapy for fistulizing Crohn's disease (ACCENT II)
Frequently Asked Questions
Did vedolizumab beat adalimumab in the VARSITY head-to-head UC trial?
Is upadacitinib approved for both UC and Crohn disease?
When should mechanism switching be used after biologic failure in IBD?
What is the JAK inhibitor safety concern in IBD?
Which biologic is preferred for perianal Crohn disease?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine